Leukemia is the most common malignant disease of the hematologic system. In addition to chronic granulocytic leukemia, acute leukemia and chronic lymphocytic leukemia all have a number of different prognostic indicators, depending on which indicators these patients can be classified into different prognostic levels and thus treated with different intensities.
The most effective approach for some patients with leukemia is often a bone marrow transplant, along with the general need for allogeneic hematopoietic stem cell transplantation. About 60% of adult patients with acute leukemia can have a long survival of more than 3 years with allogeneic or allogeneic bone marrow transplantation, and some can have more than 5 to 6 years.
The success rate of leukemia bone marrow transplantation varies markedly by leukemia type, by individual, and by transplantation modality. Clinically, if a monozygotic patient is taken as the source of bone marrow transplantation, the success rate of bone marrow is high, reaching more than 90% or even higher than 95%; if a hemizygous bone marrow transplant is taken, the success rate is generally between 50% and 80%; if a fully matched unrelated donor is taken, the success rate of bone marrow transplantation is generally around 80%. So there will be a significant difference in bone marrow transplant success rates for different leukemia types and different bone marrow sources.
Also, a successful match is only the first step in bone marrow transplantation, and treatment is influenced by many factors, such as: transplant chemotherapy hurdles, transplant hurdles, post-transplant immune rejection, and infection.